Newly launched in 2024! Lorlatinib latest price list

Lorlatinib is an innovative targeted therapy drug that is a tyrosine kinase inhibitor specifically used to treat ALK (tyrosine kinase) or ROS1 (ROS) in non-small cell lung cancer (NSCLC) Patients with proto-oncogene 1) gene mutations.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For specific medical insurance reimbursement prices, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

As a third-generationALK inhibitor, lorlatinib has high selectivity and potent anti-tumor activity. Its unique feature is that it can effectively cross the blood-brain barrier, so it has shown significant results in the treatment of NSCLC patients with brain metastasis, filling the treatment gap in this field.

One of the key properties of lorlatinib is its inhibitory effect against a variety ofALK mutations, including those that confer resistance to otherALK inhibitors. This makes lorlatinib an important first-line treatment option, especially for patients who have experienced failure of other treatments.

Clinical trial data show that lorlatinib exhibits significant anti-tumor activity in NSCLC patients with ALK or ROS1 gene mutations. The results of the CROWN study showed that lorlatinib significantly prolonged the progression-free survival of patients compared with standard treatment, bringing new treatment hope to this patient group.

However, like all drugs, lorlatinib may cause a range of side effects, including visual disturbances, gastrointestinal discomfort, liver function abnormalities, etc. Therefore, before using lorlatinib, patients need to undergo a detailed medical evaluation to ensure the safety and effectiveness of the drug, and undergo regular monitoring during treatment.